Senate Hearing on Mylan (MYL) EpiPen Pricing Likely in the Works - Evercore ISI
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Evercore ISI Mylan (NASDAQ: MYL) analyst Umer Raffat points out that a Senate hearing is likely in the works on EpiPen pricing, based on commentary in today's letter written by Chairman and Ranking Member of Senate Aging Committee.
In the letter, Mylan is being asked to brief the Committee staff within 2 weeks.
"... hearing likely in the works it seems," he said.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mylan Launches First Generics of Benicar® and Benicar HCT® Tablets
- Callidus Software (CALD) Said Mentioned Cautiously at Off Wall Street
- Jefferies Raises Price Target on Northrop Grumman (NOC) Following 3Q Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Trader Talk
Related EntitiesUmer Raffat
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!